David C. Hastings's Insider Trades & SAST Disclosures
David C. Hastings's most recent trade in Arbutus Biopharma Corp was a trade of 365,800 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 14, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern David C. Hastings.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Arbutus Biopharma Corp | David C. Hastings | Chief Financial Officer | 14 Feb 2025 | 365,800 | 365,800 | - | - | Stock Option (Right to Buy) | ||
| Arbutus Biopharma Corp | David C. Hastings | Chief Financial Officer | 14 Feb 2025 | 90,100 | 249,824 (0%) | 0% | 0 | Common Shares | ||
| Arbutus Biopharma Corp | David C. Hastings | Chief Financial Officer | 04 Feb 2025 | 22,183 | 159,724 (0%) | 0% | 3.3 | 72,827 | Common Shares | |
| Scynexis Inc | David C. Hastings | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 23,000 | 23,000 | - | - | Stock Option | |
| Scynexis Inc | David C. Hastings | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 23,000 | 46,183 (0%) | 0% | 0 | Common Stock | |
| Arbutus Biopharma Corp | C. Hastings David | Chief Financial Officer | 01 Feb 2024 | 450,000 | 450,000 | - | - | Stock Option (Right to Buy) | ||
| Arbutus Biopharma Corp | Hastings C. David | Chief Financial Officer | 01 Feb 2024 | 112,500 | 191,500 (0%) | 0% | 0 | Common Shares | ||
| Arbutus Biopharma Corp | Hastings C. David | Chief Financial Officer | 01 Feb 2024 | 9,593 | 181,907 (0%) | 0% | 2.3 | 22,184 | Common Shares | |
| Scynexis Inc | David C. Hastings | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 10,000 | 23,183 (0%) | 0% | 0 | Common Stock | |
| Scynexis Inc | David C. Hastings | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 10,000 | 10,000 | - | - | Stock Option | |
| Arbutus Biopharma Corp | David C. Hastings | Chief Financial Officer | 01 Feb 2023 | 316,000 | 316,000 | - | - | Stock Option (Right to Buy) | ||
| Arbutus Biopharma Corp | David C. Hastings | Chief Financial Officer | 01 Feb 2023 | 79,000 | 79,000 (0%) | 0% | 0 | Common Shares | ||
| Scynexis Inc | David C. Hastings | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Scynexis Inc | David C. Hastings | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 10,000 | 13,183 (0%) | 0% | 0 | Common Stock | |
| Arbutus Biopharma Corp | David C. Hastings | Chief Financial Officer | 20 Jan 2022 | 285,000 | 285,000 | - | - | Stock Option (Right to Buy) | ||
| Scynexis Inc | David C. Hastings | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Arbutus Biopharma Corp | David C. Hastings | Chief Financial Officer | 13 Feb 2021 | 250,000 | 250,000 | - | - | Stock Options | ||
| Scynexis Inc | David C. Hastings | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jul 2020 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges